

TFW 1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Yongfeng Wang et al.



Application No.: 10/559,516

Filing Date: March 27, 2006

For: 2-substituted phenyl-5, 7-dehydrocarbyl-3, 7-dihydropyrrolo [2, 3-d] pyrimidin-4-one derivatives, the preparation and the pharmaceutical use thereof

Group Art Unit: 1614

Examiner: Not Yet Assigned

Attorney Docket No.: 601/4

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant respectfully submits this Information Disclosure Statement, identification of the information, and copies thereof if required pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98 in order to comply with the duty of disclosure. The enclosed Form PTO SB/08A/B identifies the references of which Applicant is aware. The Examiner is respectfully requested to consider the information herein and make it of record in the subject application.

☒ By checking this paragraph, this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b) within three months of the filing date of the application or before the application has received a substantive Office Action. Accordingly, no fee is necessary; however, should the Patent Office determine that a fee is due, the Commissioner is authorized to charge any such fee to Deposit Account No. 11-0223.

☐ By checking this paragraph, this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(c) before the mailing date of a Final Action, a Notice of Allowance, or close of prosecution. Accordingly included herewith is:

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Dated: June 14, 2006 Signature: Ute H. Wojtkowski Print Name: Ute H. Wojtkowski

- ☐ a completed Credit Card form to cover the fee under 37 C.F.R. § 1.17(p), the Commissioner is authorized to charge any further fee to Deposit Account No. 11-0223; **or**
- ☐ a statement below under 37 C.F.R. § 1.97(e).
- ☐ By checking this paragraph, this Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(d) after the mailing date of a Final Action, a Notice of Allowance, or close of prosecution, but before payment of the issue fee. Accordingly included herewith are:
- ☐ a check to cover the fee under 37 C.F.R. § 1.17(p), the Commissioner is authorized to charge any further fee to Deposit Account No. 11-0223; **and**
- ☐ a statement below under 37 C.F.R. § 1.97(e).

Statement Pursuant to 37 C.F.R. § 1.97(e):

- ☐ By checking this paragraph, the undersigned states that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior the filing of this Information Disclosure Statement; or
- ☐ By checking this paragraph, the undersigned states that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent in a counterpart foreign application, and, the undersigned, after making reasonable inquiry, believes that no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Dated: June 14, 2006

Respectfully submitted,
By: 
Timothy X. Gibson
Registration No. 40,618
KAPLAN GILMAN GIBSON & DERNIER LLP
900 Route 9 North
Woodbridge, New Jersey 07095
Telephone (732) 634-7634
Attorneys for Applicant

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

JUN 19 2006

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 1

Application Number	10/559,516
Filing Date	March 27, 2006
First Named Inventor	Yongfeng Wang
Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	601/4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	Shen JING et al., Synthesis of Sildenafil, Chinese Academy of Medical Sciences, 1999, 9(3) pp. 220-222.	✓

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.